Source: International Congress 2014 – Markers
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Schembri, R. Flynn, A. Hapca, I. Mackenzie, T. MacDonald (Dundee, United Kingdom). Association between inhaled corticosteroid use in COPD and incidence or worsening of type2 diabetes. Eur Respir J 2014; 44: Suppl. 58, 565

Member's Comments

No comment yet.

Related content which might interest you: Prescribing patterns for UK patients commencing first maintenance therapy for COPD Source: International Congress 2014 – COPD markers Year: 2014 Mukoregulatory drugs in treating COPD Source: International Congress 2014 – Predictors Year: 2014 Characterising patterns of prescribing for UK COPD patients with comorbidities or history of pneumonia Source: International Congress 2014 – COPD exacerbations Year: 2014 Roflumilast added to triple therapy in severe COPD patients with frequent exacerbations: Efficacy and tolerability Source: International Congress 2014 – Markers Year: 2014 Clinical and inhaled drug profile of COPD patients with indication for beta-blockers who are on beta-blockers Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 COPD and depression: Prevalence and interaction Source: International Congress 2014 – Comorbidities Year: 2014 COPD on anti-GERD therapy remains at higher risk for severe exacerbation Source: International Congress 2014 – COPD exacerbations Year: 2014 Metabolic syndrome in patients with COPD Source: International Congress 2014 – Clinical presentations Year: 2014 Efficacy of roflumilast with concomitant cardiovascular medication in patients with COPD Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management Year: 2013 The role of COPD in development of osteoporosis Source: International Congress 2014 – Markers Year: 2014 Is therapy adherence to inhaled corticosteroids related to hospitalization, pneumonia or mortality in COPD? Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 The clinical impact of long-acting bronchodilators in newly diagnosed COPD patients Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 The influence of type of inhalation device on adherence of COPD patients to inhaled medication Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013 Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Differences in adherence to common inhaled medications in COPD Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013 The parameters that may affect inhalation therapy success in elderly COPD and asthma patients Source: International Congress 2015 – Co-existing diseases and asthma Year: 2015 Impact of hyperglycaemia and comorbid diabetes mellitus on short and long-term outcome after COPD exacerbation Source: Annual Congress 2013 –Monitoring respiratory diseases: role of comorbidities and lung involvement Year: 2013 Is therapy adherence with inhaled tiotropium in COPD related to hospitalization, pneumonia or mortality? Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Impact of frequent exacerbations in patients with COPD Source: International Congress 2014 – Clinical presentations Year: 2014 Diabetes and hospitalization for COPD exacerbation Source: International Congress 2016 – Features and impact of comorbidities in COPD Year: 2016